Singaporean intestine microbiome agency AMILI brings house $10.5M in Collection A funding


Share post:

Singapore-based precision intestine microbiome firm AMILI has snapped up $10.5 million in a Collection A funding spherical led by know-how and life sciences investor Vulcan Capital. 

New buyers additionally joined the spherical, together with Pruksa Group, TVM Capital Healthcare, Emtek Group, Capital Code, Pureland Group, Blue7 and Enterprise Singapore’s funding arm SEEDS Capital.


Based in 2019, the corporate is constructing an enormous multi-ethnic repository of microbiome information and samples from Asia, together with the one present microbiome financial institution in Southeast Asia. Additionally it is growing diagnostics assessments, predictive algorithms, and microbiome-modifying interventions by means of its proprietary analytics engine known as AMILI Prime.

Its database is used to help tutorial establishments and biotech corporations in figuring out new biomarkers for the formulation of intestine well being merchandise, in addition to providing insights to meals producers.

Not too long ago, AMILI launched in Singapore its shopper well being model BIO & ME, which affords probiotics and diagnostic assessments based mostly by itself microbiome database. The model is focused to be rolled out in the remainder of Southeast Asia and in Hong Kong later this 12 months. 

Moreover, the corporate affords faecal microbiota transplants to assist deal with bacterial infections.


In line with a press assertion, the recent funds will likely be used for its additional growth in Southeast Asia within the close to time period and in the remainder of Asia later. It’s going to additionally help its pursuit of extra analysis partnerships and discovery, in addition to the event of AMILI Prime.


Whereas there was development in intestine well being analysis worldwide in recent times, “there may be nonetheless an enormous hole in analysis that’s consultant of the Asian inhabitants,” claimed Tommy Teo, managing director of Vulcan Capital.

Presently, AMILI focuses its scientific analysis on three areas: well being and wellness, oncology, and response to microbiome-based therapeutics. Since 2019, it has performed over 20 analysis research – valued at over $40 million – throughout a spread of well being indications.


Different microbiome gamers within the world market have additionally drawn buyers’ cash in recent times. US-based Viome Life Sciences, which affords microbiome assessments and identifies biomarkers for persistent illnesses, closed $54 million in a pre-Collection C spherical in November. Its newest funds will help its scientific research aimed toward growing early-stage diagnostics and therapeutics.

One other firm, Ombre, raised $3 million in seed funding, which will likely be used to reinforce the intestine well being experiences and probiotic suggestions on its cellular app.

Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles